Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Liabilities and Shareholders Equity (2017 - 2025)

Entera Bio has reported Liabilities and Shareholders Equity over the past 9 years, most recently at $16.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 70.32% year-over-year to $16.0 million, compared with a TTM value of $74.7 million through Dec 2025, up 99.62%, and an annual FY2025 reading of $16.0 million, up 70.32% over the prior year.
  • Liabilities and Shareholders Equity came in at $16.0 million for Q4 2025, down from $17.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $29.1 million in Q3 2021 to a low of $7.7 million in Q3 2024.
  • Median Liabilities and Shareholders Equity over the past 5 years was $15.8 million (2022), compared with a mean of $16.4 million.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 231.62% in 2021, then tumbled 49.49% in 2022.
  • Over 5 years, Liabilities and Shareholders Equity stood at $26.0 million in 2021, then tumbled by 49.49% to $13.1 million in 2022, then dropped by 10.38% to $11.8 million in 2023, then decreased by 20.19% to $9.4 million in 2024, then skyrocketed by 70.32% to $16.0 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Liabilities and Shareholders Equity are $16.0 million (Q4 2025), $17.4 million (Q3 2025), and $19.7 million (Q2 2025).